David I. Bernstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David I. Bernstein has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
A. Wanderer
1 shared publicationA.F. Finn
1 shared publicationA.T. Segal
1 shared publicationAndré Cartier
Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio; Laboratoire de Pneumologie-Researche, Hôpital du Sacré Coeur de Montreal, Montreal; and Institut de Cardiologie et de Pneumologie de L'Université Laval, Hôpital Laval, Sainte-Foy, Québec, Canada
1 shared publicationBrian Berendts
1 shared publicationC. Laforce
1 shared publication
Latest Publications
- 1 May 2003
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 23 (2) , 221-234
Occupational asthma caused by exposure to low-molecular-weight chemicals
- 1 May 2003
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 23 (2) , 221-234
Occupational asthma caused by exposure to low-molecular-weight chemicals
- 1 February 2003
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 90 (2) , 209-213
Clinical and occupational outcomes in health care workers with natural rubber latex allergy
- 1 February 2003
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 90 (2) , 209-213
Clinical and occupational outcomes in health care workers with natural rubber latex allergy
- 15 August 2002
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 166 (4) , 445-450
Diisocyanate Antigen-stimulated Monocyte Chemoattractant Protein-1 Synthesis Has Greater Test Efficiency than Specific Antibodies for Identification of Diisocyanate Asthma
We previously reported that diisocyanate-human serum albumin (DIISO-HSA) stimulated production of monocyte chemoattractant protein-1 (MCP-1) by peripheral blood mononuclear cells is significantly associated with a clinical diagnosis of diisocyanate asthma (DA). Others have reported that antibodies for DIISO-HSA are specific but insensitive markers of DA. This study was performed to evaluate test characteristics of the in vitro MCP-1 assay compared with DIISO-HSA–specific immunoglobulin (Ig) G and IgE in identifying workers with DA. MCP-1 was quantitated in peripheral blood mononuclear cell supernatants 48 hours after incubation with DIISO-HSA antigens. Assay results were compared with outcomes of specific inhalation challenge (SIC) testing. Nineteen of 54 (35%) workers assayed for antibodies and MCP-1 stimulation had SIC-confirmed DA. Mean MCP-1 produced by SIC-positive workers was greater than SIC-negative workers (p ⩽ 0.001). Diagnostic sensitivity, specificity, and test efficiency for specific IgG were 47%, 74%, and 65%, respectively, and for specific IgE were 21%, 89%, and 65%, respectively. Sensitivity, specificity, and test efficiency of the MCP-1 test were 79%, 91%, and 87%, respectively. This study indicates that the MCP-1 stimulation assay has greater sensitivity and specificity than the specific antibody assays in correctly identifying DA.
- 15 August 2002
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 166 (4) , 445-450
Diisocyanate Antigen-stimulated Monocyte Chemoattractant Protein-1 Synthesis Has Greater Test Efficiency than Specific Antibodies for Identification of Diisocyanate Asthma
We previously reported that diisocyanate-human serum albumin (DIISO-HSA) stimulated production of monocyte chemoattractant protein-1 (MCP-1) by peripheral blood mononuclear cells is significantly associated with a clinical diagnosis of diisocyanate asthma (DA). Others have reported that antibodies for DIISO-HSA are specific but insensitive markers of DA. This study was performed to evaluate test characteristics of the in vitro MCP-1 assay compared with DIISO-HSA–specific immunoglobulin (Ig) G and IgE in identifying workers with DA. MCP-1 was quantitated in peripheral blood mononuclear cell supernatants 48 hours after incubation with DIISO-HSA antigens. Assay results were compared with outcomes of specific inhalation challenge (SIC) testing. Nineteen of 54 (35%) workers assayed for antibodies and MCP-1 stimulation had SIC-confirmed DA. Mean MCP-1 produced by SIC-positive workers was greater than SIC-negative workers (p ⩽ 0.001). Diagnostic sensitivity, specificity, and test efficiency for specific IgG were 47%, 74%, and 65%, respectively, and for specific IgE were 21%, 89%, and 65%, respectively. Sensitivity, specificity, and test efficiency of the MCP-1 test were 79%, 91%, and 87%, respectively. This study indicates that the MCP-1 stimulation assay has greater sensitivity and specificity than the specific antibody assays in correctly identifying DA.
- 1 September 1999
- Published by Elsevier in Respiratory Medicine
- Vol. 93 (9) , 603-612
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler
- 1 September 1999
- Published by Elsevier in Respiratory Medicine
- Vol. 93 (9) , 603-612
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler